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Abstract
Background: Local‐regional failure (LF) for locally advanced bladder cancer
(LABC) after radical cystectomy (RC) is common even with chemotherapy and is
associated with high morbidity/mortality. Postoperative radiotherapy (PORT) can
reduce LF and may enhance overall survival (OS) but has no defined role. We hypothesized that the addition of PORT would improve OS in LABC in a large nationwide oncology database.
Methods: We identified ≥ pT3pN0‐3M0 LABC patients in the National Cancer
Database diagnosed 2004‐2014 who underwent RC ± PORT. OS was calculated
using Kaplan‐Meier and Cox proportional hazards regression modeling was used to
identify predictors of OS. Propensity matching was performed to match RC patients
who received PORT vs those who did not.
Results: 15,124 RC patients were identified with 512 (3.3%) receiving PORT.
Median OS was 20.0 months (95% CI, 18.2‐21.8) for PORT vs 20.8 months (95% CI,
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20.3‐21.3) for no PORT (P = 0.178). In multivariable analysis, PORT was independently associated with improved OS: hazard ratio 0.87 (95% CI, 0.78‐0.97); P = 0.008.
A one‐to‐three propensity match yielded 1,858 patients (24.9% receiving PORT and
75.1% without). In the propensity‐matched cohort, median OS was 19.8 months (95%
CI, 18.0‐21.6) for PORT vs 16.9 months (95% CI, 15.6‐18.1) for no PORT
(P = 0.030). In the propensity‐matched cohort of urothelial carcinoma patients
(N = 1,460), PORT was associated with improved OS for pT4, pN+, and positive
margins (P < 0.01 all).
Conclusion: In this observational cohort, PORT was associated with improved OS in
LABC. While the data should be interpreted cautiously, these results lend support to
the use of PORT in selected patients with LABC, regardless of histology. Prospective
trials of PORT are warranted.
KEYWORDS
adjuvant radiation therapy, bladder cancer, PORT
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IN T RO D U C T ION

Local‐regional failure (LF) for locally advanced bladder cancer (LABC) after radical cystectomy (RC) is common, and
is associated with high morbidity and mortality.1-3 Adjuvant
chemotherapy has not been shown in randomized prospective trials to reduce the risk of LFs,1,4 and salvage strategies
after LF are rarely successful.2,5,6 Postoperative radiotherapy
(PORT) has been shown to significantly reduce local failures
and may enhance survival.7,8 A recently published phase II
randomized trial in Egypt of patients with LABC status post
RC and pelvic lymph node dissection with negative margins
reported significantly improved local control with the addition of PORT vs adjuvant chemotherapy alone, with 2‐year
local control of 96% for sequential chemotherapy plus PORT
vs 69% for chemotherapy alone (P < 0.01).8 Disease‐free
survival and overall survival (OS) were improved with the
addition of PORT but the study was not powered for those
endpoints. While only 53% of the patients had urothelial carcinoma, outcomes did not differ based on histology.
Interest in PORT after RC has increased in Europe and
North America, and researchers have identified an externally
validated risk stratification for selecting patients at highest
risk for local failure who are most likely to benefit from
PORT and have mapped the patterns of failure in the pelvis to
design consensus target volumes.1,9-13 An NRG randomized
phase II trial of PORT vs no PORT (NRG‐GU001) opened
in 2015 in the US and Canada but closed early due to poor
accrual. Other trials of PORT in Europe, India, and Egypt
have opened, but are not powered for an OS endpoint.14 It
is unlikely that a randomized trial of sufficient size can be
conducted in the West to assess whether PORT improves

OS, and large retrospective series are lacking. The purpose
of this study is to investigate whether the addition of PORT
improved OS using the National Cancer Database (NCDB), a
database of sufficient size to potentially answer the question.
We hypothesized that the addition of PORT would improve
overall survival in patients with LABC.

2
2.1

|

M ATERIAL S AND M ETHO D S

|

Study population

The NCDB Participant User File for bladder tumors was reviewed to identify all patients 18‐90 years old diagnosed with
bladder cancer from 2004 to 2014. Data from approximately
70% of the patients diagnosed at Commission on Cancer‐accredited cancer centers is incorporated and includes patient,
tumor, and treatment characteristics. The Participant User
File contains de‐identified patient and center information and
was exempt from Institutional Review Board review.
From this dataset, we selected a cohort of patients who
would have been eligible for the NRG‐GU001 study as follows. All patients included received cystectomy as defined
by cystectomy, RC, or more advanced surgical procedure
(ie, exenteration). Only patients with pT3‐4,N0‐3,M0 disease, known surgical margin status, nonsmall cell and nonlymphoma histology, and known chemotherapy details were
included. Additionally, those patients who died within 30
days of surgery or did not have follow‐up information were
excluded. Lastly, patients with more favorable disease characteristics (pT3a,N0 and ≥ 10 LN dissected, and negative
surgical margins) were excluded as these patients have been
shown to have lower risk of LF and were excluded from
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NRG‐GU001.10 Patients were classified into two cohorts:
postoperative radiotherapy (PORT) vs no PORT. Patients included in the PORT cohort received postoperative external
beam radiotherapy to the pelvis/cystectomy bed within 1 year
of surgery to a total dose of ≥ 40 Gy. Patients receiving palliative pelvic radiation therapy as coded by the NCDB were
excluded. Patients who died within 30 days of surgery were
excluded. Patient CONSORT diagram detailing complete inclusion criteria is found in Figure S1.
Patient characteristics for analysis included: age, sex, race,
Charlson‐Deyo comorbidity index (CCI), treatment facility
type, primary insurance status, histology, pathologic T‐stage,
pathologic N‐stage, number of regional nodes examined, surgical margin status, receipt of chemotherapy (both neoadjuvant and adjuvant), and receipt of radiotherapy. The primary
endpoint was overall survival.

2.2

|

Statistical analysis

The chi‐squared test was used to compare categorical demographic and patient characteristics between the two treatment
groups. The Student's t test was used to compare continuous
variables between groups. Overall survival was calculated
from diagnosis until death, censoring at last follow‐up for
patients who were alive. The Kaplan‐Meier method was used
to estimate overall survival probabilities. Univariable (UVA)
and multivariable analysis (MVA) logistic regression modeling were used to identify predictors of receiving adjuvant
radiotherapy and are reported as odds ratios. UVA and MVA
Cox proportional hazard modeling were used to identify factors associated with overall survival and are reported as hazard ratios (HR) with corresponding 95% confidence intervals.
The MVA models were created by including all covariates
and then removing each covariate with a P value > 0.2 in
a step‐wise method. Categorical covariates were included in
the final model if the covariate levels in comparison with the
reference group had a P value < 0.1.15 To confirm appropriate selection of predictive variables entered into multivariable analysis, a stepwise regression was utilized. Proportional
hazards assumptions were tested using Schoenfeld residuals
tests and were not violated. P < 0.05 was considered significant. All were two‐sided.
Since observational studies are susceptible to unmeasured
confounding, we conducted a regression‐based sensitivity
analysis in which we evaluated the sensitivity of our Cox
HR to the presence of a binary confounder (such as patient
functional status which was not available in our dataset). We
varied the prevalence and strength of the unmeasured confounder to assess whether our primary findings would be altered if in fact we could have adjusted for the unmeasured
confounder.16
A secondary propensity score (PS) matched analysis
was conducted to better potentially account for differences

FISCHER‐VALUCK et al.

in baseline patient characteristics between the PORT and no
PORT groups. Matching was performed based on patient
characteristics and disease factors that included: age, sex,
race, CCI, facility type, insurance status, histology, pathologic T‐stage, pathologic N‐stage, margin status, number of
nodes examined, and chemotherapy treatment information
including neoadjuvant vs adjuvant. One‐to‐three matching
using nearest‐neighbor algorithm assuming independent observations and fixed weights was performed. Caliper width
was narrowed in a stepwise fashion until the covariate distributions were balanced after matching.17 A caliper width
of 0.2 was used in subsequent analyses. Balancing of groups
after PS matching was verified using the χ2 test for categorical variables and the t test for continuous variables as well
as comparing standardized differences of baseline covariates
between the PORT and no PORT groups. After matching, a
matched‐sample UVA Cox regression model was applied to
the matched groups to estimate the effect of treatment on survival.18 Forest plots were generated after PS matching using
UVA Cox regression to analyze the subgroup interactions.
SPSS Statistics v.23 (IBM Corporation; Armonk, NY) was
used for all statistical analyses.

3

|

RESULTS

3.1 | Demographics and factors associated
with receipt of PORT
Of the 484,367 patients diagnosed with bladder cancer from
2004 to 2014 in the NCDB, we identified 15,124 patients
who met inclusion criteria (Figure S1). Median follow‐up
was 18.8 months (25‐75th quartile: 9.8‐39.0 months). Five
hundred and twelve (3.3%) of the patients received PORT.
Median time from surgery to PORT was 110 days [25‐75th
quartile: 52‐188 days]. Median radiation dose was 50.4 Gy
[25‐75th quartile: 45‐55.80 Gy]. Median age of patients
receiving PORT was 65 years vs 69 years for no PORT
(P < 0.0001). Baseline patient characteristics are listed in
Table 1. Multivariable logistic regression showed that cofactors associated with increased likelihood for PORT included:
female gender, nonurothelial histology, pathologic T4 stage,
positive surgical margins, and receipt of chemotherapy
(Table 2).

3.2

|

Survival analysis

The median follow‐up for patients receiving PORT was
18.6 months vs 18.8 months in the no PORT group. The median OS was 20.0 months (95% CI, 18.2‐21.8) for the PORT
group vs 20.8 months (95% CI, 20.3‐21.3) for the group that
did not receive PORT (P = 0.178) (Figure S2). For patients
with pT4 disease, the median OS was 17.9 months (95% CI,
16.3‐19.6) for PORT vs 15.9 months (95% CI, 15.2‐16.5)
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Demographics and clinical characteristics
Number of Patients
No PORT

PORT

14,612 (96.7%)

512 (3.3%)

Mean

68.0

64.6

SD

10.6

10.8

Median

69

65

Range

22‐90

32‐90

Male

10,583 (72.4%)

319 (62.3%)

Female

4,029 (27.6%)

193 (37.7%)

White

13,240 (90.6%)

452 (88.3%)

Other

1,372 (9.4%)

60 (11.7%)

0

10,228 (70.0%)

375 (73.2%)

1

3,328 (22.8%)

101 (19.7%)

≥2

1,056 (7.2%)

36 (7.0%)

Academic/Research Program

7,248 (49.6%)

157 (30.7%)

Other

7,263 (49.7%)

346 (67.6%)

Unknown

101 (0.7%)

9 (1.8%)

Private

4,470 (30.6%)

185 (36.1%)

Other

10,142 (69.4%)

327 (63.9%)

Urothelial

12,972 (88.8%)

389 (76.0%)

Squamous

860 (5.9%)

69 (13.5%)

Adeno

271 (1.9%)

22 (4.3%)

Other (excluding small cell/lymphoma)

509 (3.5%)

32 (6.3%)

T3

9,729 (66.6%)

219 (42.8%)

T4

4,883 (33.4%)

293 (57.2%)

No

7,678 (52.5%)

258 (50.4%)

Yes

6,934 (47.5%)

254 (49.6%)

Mean

12.9

10.3

SD

12.3

10.2

Median

9.0

8.0

Range

0‐90

0‐62

No

11,707 (80.1%)

249 (48.6%)

Yes

2,905 (19.9%)

263 (51.4%)

N

P‐Value
<0.0001

Age, years

Sex
<0.0001

Race
0.074

Charlson‐Deyo Comorbidity:
0.247

Facility Type
<0.0001

Insurance Status
0.004

Histology
<0.0001

Pathologic T‐stage
<0.0001

Positive Lymph Nodes
0.345

Number of Regional Lymph Nodes Examined
0.946

Positive surgical margins
<0.0001

Chemotherapy
(Continues)
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(Continued)
Number of Patients
No PORT

PORT

P‐Value

None

8,329 (57.0%)

119 (23.2%)

<0.0001

Single‐agent

474 (3.2%)

98 (19.1%)

Multi‐agent

5,382 (36.8%)

263 (51.4%)

Number of agents unknown

428 (2.9%)

32 (6.3%)
<0.0001

Chemotherapy Sequence
None

8,201 (56.1%)

118 (23.0%)

Neoadjuvant

1,405 (9.6%)

48 (9.4%)

Adjuvant

4,311 (29.5%)

311 (60.7%)

Both

415 (2.8%)

23 (4.5%)

Unknown

280 (1.9%)

12 (2.3%)

for no PORT (P = 0.232) (Figure 1A). Patients with node‐
positive disease had a median OS of 20.1 months (95% CI,
17.1‐23.2) for PORT vs 17.0 (95% CI, 16.5‐17.5) for no
PORT (P = 0.133) (Figure 1B). For patients with positive
surgical margins, the median OS was 17.9 months (95% CI,
15.6‐20.1) for PORT vs 12.8 months (95% CI, 12.2‐13.4)
for no PORT (P < 0.0001) (Figure 1C). For patients with
both pT4 disease and positive surgical margins, the median OS was 17.3 months (95% CI, 15.8‐18.8) for PORT vs
11.7 months (95% CI, 11.1‐12.2) for no PORT (P < 0.0001)
(Figure 1D). In multivariable analysis, PORT was independently associated with an improved OS (HR: 0.87 [95% CI,
0.78‐0.97]; P = 0.008) (Table 3).

3.3

|

Sensitivity analysis

We performed a sensitivity analysis to assess the potential
effect of unmeasured confounding on the primary outcome
of overall survival. We chose patient functional status, which
was not available to us in this study, although the analysis would apply to other unmeasured confounders, such as
smoking status. Our sensitivity analysis showed that if there
was an unmeasured confounder with a deleterious effect on
OS with a HR of 1.25 and was 9% more common in the no
PORT cohort, adjusting for it would not change the overall
findings that PORT is associated with significantly improved
OS (updated HR 0.90, 95% CI 0.80‐0.99). If the prevalence
of the deleterious unmeasured confounder in the control
group was much greater, for example 20% higher, PORT
would no longer be statistically significant (HR 0.90, 95%
CI 0.85‐1.04).

3.4

|

Matched analysis

A one‐to‐three propensity match yielded a total of 1,858 patients (24.9% receiving PORT and 75.1% without receipt of

PORT) (Table S1). In the propensity‐matched cohort, median
OS was 19.8 months (95% CI, 18.0‐21.6) for the PORT group
vs 16.9 months (95% CI, 15.6‐18.1) for the group that did not
receive PORT (log‐rank P = 0.030, Wilcoxon P < 0.0001,
Tarone‐Ware P < 0.0001) (Figure 2A). For patients with pT4
disease, the median OS was 17.9 months (95% CI, 16.2‐19.4)
for PORT vs 13.2 months (95% CI, 12.2‐14.3) for no PORT
(P = 0.003) (Figure 2B). For patients with node‐positive disease, the median OS was 20.2 months (95% CI, 17.4‐23.0) for
PORT vs 15.1 (95% CI, 13.7‐16.4) for no PORT (P = 0.003)
(Figure 2C). For patients with positive surgical margins, the
median OS was 17.8 months (95% CI, 15.8‐19.8) for PORT
vs 12.4 months (95% CI, 11.5‐13.2) for no PORT (P = 0.002)
(Figure 2D). For patients with both pT4 disease and positive
surgical margins, the median OS was 17.2 months (95% CI,
15.8‐18.6) for PORT vs 11.9 months (95% CI, 11.0‐12.7)
for no PORT (P < 0.0001) (Figure 2E). PORT was independently associated with improved OS in the matched cohort
(HR: 0.88 [95% CI, 0.77‐0.98]; P = 0.030). A forest plot of
tumor and treatment characteristics and their association with
OS is depicted in Figure 3.

3.5

|

Urothelial cohort

From the propensity‐matched cohort, 1,460 patients with
urothelial histology were identified. Three hundred and
fifty‐seven (24.5%) patients in this subgroup received
PORT and 1,103 (75.5%) patients did not receive PORT.
Other patient characteristics and receipt of chemotherapy in
the urothelial cohort were well balanced (data not shown).
Median OS was 20.2 months (95% CI, 18.2‐22.3) for the
patients that received PORT compared to 17.2 months (95%
CI, 15.8‐18.2) for no PORT (P = 0.099). For urothelial patients with pT4 disease, the median OS was 18.6 months
(95% CI, 16.4‐20.8) for PORT vs 13.6 months (95% CI,
12.3‐14.8) for no PORT (P = 0.007) (Figure S3A). For
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Univariable and multivariable logistic regression for receipt of adjuvant RT
Univariate

Multivariate

Odds ratio

P‐Value

Odds ratio

P‐Value

0.97 (0.96‐0.98)

<0.0001

0.98 (0.97‐0.99)

0.003

<0.0001

1.47 (1.20‐1.80)

0.095

0.82 (0.61‐1.11)

Age
Years
Sex
Male

Reference Group

Female

1.57 (1.31‐1.89)

Reference Group
<0.0001

Race
White

Reference Group

Other

0.79 (0.60‐1.04)

Reference Group
0.201

Charlson‐Deyo Comorbidity:
0

Reference Group

Reference Group

1

0.83 (0.66‐1.04)

0.109

0.93 (0.73‐1.18)

0.456

≥2

0.93 (0.63‐1.29)

0.558

1.12 (0.77‐1.63)

0.434

<0.0001

0.48 (0.39‐0.60)

<0.0001

Facility Type
Academic/Research Program

0.45 (0.37‐0.55)

Other

Reference Group

Unknown

1.92 (0.96‐3.82)

0.075

0.91 (0.41‐2.03)

0.816

Private Insurance

1.29 (1.07‐1.56)

0.008

1.03 (0.82‐1.29)

0.790

Other

Reference Group

Reference Group

Insurance Status
Reference Group

Histology
Urothelial

Reference Group

Squamous

2.70 (2.07‐3.53)

<0.0001

2.65 (1.96‐3.60)

Reference Group
<0.0001

Adeno

2.51 (1.58‐4.00)

<0.0001

2.07 (1.24‐3.44)

0.005

Other (excluding small cell/
lymphoma)

2.15 (1.49‐3.12)

<0.0001

1.59 (1.06‐2.39)

0.025

<0.0001

2.04 (1.67‐2.49)

Pathologic T‐stage
T3

Reference Group

T4

2.84 (2.37‐3.40)

Reference Group
<0.0001

Positive Lymph Nodes
No

Reference Group

Reference Group

Yes

1.15 (0.96‐1.38)

0.125

0.90 (0.74‐1.10)

0.290

Number of Regional Lymph
Nodes Examined

0.98 (0.97‐0.99)

<0.0001

0.98 (0.97‐0.99)

<0.0001

<0.0001

3.31 (2.71‐4.03)

<0.0001

4.66 (3.03‐7.17)

Positive Surgical Margins
No

Reference Group

Yes

4.50 (3.75‐5.39)

Reference Group
<0.0001

Chemotherapy
None

Reference Group

Single‐agent

5.19 (3.45‐7.80)

Reference Group
<0.0001

Multi‐agent

14.12 (10.6‐18.8)

<0.0001

11.66 (8.52‐15.9)

<0.0001

Number of agents unknown

3.44 (2.76‐4.29)

<0.0001

3.27 (2.57‐4.17)

<0.0001

patients with node‐positive disease, the median OS was
20.7 months (95% CI, 17.8‐23.6) for PORT vs 15.3 (95%
CI, 13.8‐16.9) for no PORT (P = 0.011) (Figure S3B). For

patients with positive surgical margins, the median OS was
18.3 months (95% CI, 15.9‐20.7) for PORT vs 12.9 months
(95% CI, 11.6‐14.3) for no PORT (P = 0.002) (Figure

3704
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A

B
P = 0.133

P = 0.232
PORT

PORT

No
PORT

No
PORT

pT4 disease

Node + disease

C

D
P < 0.0001

P < 0.0001
PORT

PORT

No
PORT

No
PORT

Margins +

pT4 & margins + disease

F I G U R E 1 Kaplan‐Meier overall survival curves for PORT vs no PORT in: (A) pathologic T4 (pT4) disease; (B) node positive disease;
(C) positive surgical margins; (D) both pT4 disease and positive surgical margins. PORT, postoperative radiotherapy. Green line = PORT, Blue
line = No PORT

S3C). For patients with both pT4 disease and positive surgical margins, the median OS was 17.4 months (95% CI,
15.7‐19.1) for PORT vs 11.9 months (95% CI, 10.9‐12.9)
for no PORT (P = 0.002) (Figure S3D).

4

|

D IS C U S S ION

Local‐regional failure for LABC after RC is common. In both
SWOG 8710 and Medical Research Council trials of RC with
or without neoadjuvant chemotherapy, the 5‐year incidence
of LFs for patients with ≥ pT3 urothelial carcinoma was over
30%.1,4 It has been hypothesized that reducing LFs may lead
to improved disease‐free and overall survival. From a surgical perspective, retrospective series have associated more extensive nodal dissections with improved survival outcomes,
even in the absence of nodal metastasis, which suggests that
removal of occult nodal disease may improve survival by decreasing LFs.19 Additionally, there is an evidence that local

failure often precedes but uncommonly follows the development of distant metastasis, suggesting that local failure may
seed distant disease.20 Even if LF did not reduce the risk of
DM or affect survival, there is often considerable morbidity
associated with LF and efforts to reduce LF may improve
patient quality‐of‐life.2
Given the association between LF and development of
distant disease, methods to improve local control may be
warranted and may improve survival. While the addition of
chemotherapy to RC improves overall survival, it has not
been shown in randomized prospective trials to reduce the
risk of LF.1,4 As improvements in systemic therapy further reduce the risk of distant disease, treatments designed to reduce
local recurrences will gain in importance to reduce the overall risk of relapse. Additionally, salvage strategies after LF
are rarely successful with a median survival of approximately
9 months.21,22 PORT for LABC thus offers an option to significantly improve local control, which may in turn improve
survival, but the role of PORT has not been clearly defined.
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Univariable and multivariable Cox regression for overall survival
Univariable

Postoperative RT
(PORT)

Multivariable

Hazard ratio

P‐Value

Hazard ratio

P‐Value

1.09 (0.98‐1.21)

0.101

0.87 (0.78‐0.97)

0.008

1.01 (1.01‐1.02)

<0.0001

1.01 (1.01‐1.01)

<0.0001

Age
Years
Sex
Male

Reference Group

Female

1.05 (1.01‐1.10)

Reference Group
0.013

1.03 (0.99‐1.08)

0.124

Race
White

Reference Group

Other

0.94 (0.89‐1.01)

Reference Group
0.077

0.92 (0.86‐0.98)

0.009

Charlson‐Deyo Comorbidity
0

Reference Group

1

1.21 (1.16‐1.27)

<0.0001

Reference Group
1.17 (1.12‐1.22)

<0.0001

≥2

1.35 (1.26‐1.45)

<0.0001

1.28 (1.19‐1.38)

<0.0001

Academic/Research
Program

0.95 (0.92‐0.99)

0.013

0.96 (0.93‐1.00)

0.060

Other

Reference Group

Unknown

0.86 (0.68‐1.08)

0.199

1.24 (0.98‐1.58)

0.078

Private Insurance

0.78 (0.75‐0.81)

<0.0001

0.91 (0.87‐0.96)

<0.0001

Other

Reference Group

Reference Group

Urothelial

Reference Group

Reference Group

Squamous

1.12 (1.07‐1.25)

<0.0001

1.18 (1.09‐1.28)

<0.0001

Adeno

0.89 (0.77‐1.02)

0.090

0.82 (0.72‐0.95)

0.008

Other (excluding small
cell/lymphoma)

1.22 (1.10‐1.34)

<0.0001

1.12 (1.01‐1.24)

0.025

Facility Type

Reference Group

Insurance Status

Histology

Pathologic T‐stage
T3

Reference Group

Reference Group

T3a

1.04 (0.97‐1.12)

0.230

0.98 (0.91‐1.05)

0.616

T3b

1.18 (1.10‐1.27)

<0.0001

1.21 (1.13‐1.31)

<0.0001

T4

1.52 (1.37‐1.67)

<0.0001

1.37 (1.27‐1.52)

<0.0001

T4a

1.44 (1.34‐1.54)

<0.0001

1.36 (1.27‐1.48)

<0.0001

T4b

2.21 (1.98‐2.47)

<0.0001

2.02 (1.80‐2.27)

<0.0001

Positive Lymph Nodes
No

Reference Group

Reference Group

Yes

1.45 (1.45‐1.57)

<0.0001

1.79 (1.72‐1.87)

<0.0001

Number of Regional
Lymph Nodes
Examined

0.99 (0.99‐0.99)

<0.0001

0.99 (0.99‐0.99)

<0.0001

Positive surgical margins
No

Reference Group

Yes

1.68 (1.60‐1.75)

Reference Group
<0.0001

1.51 (1.44‐1.59)

<0.0001
(Continues)
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(Continued)
Univariable
Hazard ratio

Multivariable
P‐Value

Hazard ratio

P‐Value

Chemotherapy
None

Reference Group

Reference Group

Single‐agent

0.95 (0.86‐1.05)

0.338

Multi‐agent

0.78 (0.75‐0.81)

Number of agents
unknown

0.85 (0.76‐0.95)

0.74 (0.67‐0.83)

<0.0001

<0.0001

0.69 (0.66‐0.72)

<0.0001

0.004

0.83 (0.75‐0.92)

<0.0001

Concerns for significant toxicity after PORT have been
a major reason why adoption of this adjuvant therapy has
been rather limited. Toxicity results using outdated radiotherapy techniques in the 1970s and 1980s did show relatively high rates of toxicity. However, the results of the
Zaghloul et al trial of post‐operative radiotherapy plus adjuvant chemotherapy vs adjuvant chemotherapy alone after
RC that used more modern three‐dimensional conformal radiotherapy reported low rates of late GI toxicity for PORT.8
In addition, a patterns of failure analysis by Baumann et al
demonstrated that the cystectomy bed could be safely omitted for patients with negative margins, thus significantly
reducing the amount of radiation dose to the central pelvis
since only the pelvic side wall nodes would have to be covered to full dose.9 The radiation target volumes for PORT
in patients with negative margins are routinely smaller than
those commonly used for patients with prostate cancer receiving postoperative whole pelvis radiotherapy.
The use of PORT vs no PORT following RC in patients
with LABC has not been evaluated in large, modern phase
III trials powered to detect a benefit in overall survival. A
previous randomized clinical trial of adjuvant RT vs observation conducted in the 1980s at the National Cancer
Institute in Cairo, Egypt reported a significant improvement in both local control and disease‐free survival with
PORT.7 In that study, 80% of the patients had squamous
cell carcinoma and only 20% had urothelial carcinoma but
the outcomes were equivalent independent of histology.
That trial, which used older two‐dimensional RT techniques, established PORT as a standard adjuvant treatment
for LABC in Egypt. A second randomized trial conducted
at the NCI in Cairo compared sequential PORT and chemotherapy (n = 75) vs adjuvant chemotherapy alone (n = 45)
in patients with LABC who had complete (R0) resections
and again confirmed a significant benefit in local control.8
DFS and OS were improved but the study was not powered
for those endpoints and the differences were not significant. In that trial, 53% of the patients had urothelial carcinoma, which may make these results more applicable to a
western patient population. In an unplanned subset analysis
of patients with urothelial carcinoma, the addition of PORT

was also associated with a statistically significant improvement in local control.8
Interest in PORT has grown outside of Egypt and the Middle
East, 23 and several trials of adjuvant RT have opened recently,
including a cooperative group trial in France (GETUG) and
single‐institution trials at Tata Memorial Hospital (Mumbai,
India) and Ghent University (Ghent, Belgium).14,24 The NRG
Oncology cooperative group opened a trial in 2015 to evaluate the benefit of PORT for LABC that enrolled patients
with pT3‐4 N0‐2 M0 bladder cancer after RC (NRG‐GU001).
Unfortunately, the trial closed in 2017 due to poor accrual
with insufficient patient numbers for analysis.
Given the closure of NRG‐GU001 and the challenges of
accruing patients on trials of PORT in Europe and North
America, it is unlikely that a phase III trial powered to detect
an overall survival difference could be successfully completed
in the near future. Therefore, we are limited to retrospective
analyses of large population‐based databases. Fortunately,
the selection criteria for patients who are most likely to benefit from PORT has been developed and externally validated
and this information was incorporated in the selection criteria
for NRG‐GU001.1,10,25,26 In this study, we identified a patient
population similar to the inclusion criteria for NRG‐GU001
and evaluated the role of PORT in this patient population.
We found that PORT was independently associated with
an overall survival benefit on multivariable analysis. While
important prognostic covariates such as age, T‐stage, positive
margins, and receipt of chemotherapy were not balanced between the groups, after balancing these potential confounders
with propensity matching, the association between improved
OS and PORT became statistically stronger. Additionally, we
found that the patient characteristics associated with the greatest overall survival benefit for PORT were pT4 disease, node
positive disease, and positive surgical margins, characteristics
which are associated with higher rates of local‐regional recurrence in the literature.2,22,27 We observed the same trends
in the subgroup analysis of patients with urothelial histology
with significant improvement in overall survival with the addition of PORT in pT4 disease, node positive disease, and
positive surgical margins. This is the first study to report an
overall survival benefit for PORT in LABC patients and lends
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F I G U R E 2 Kaplan‐Meier overall survival curves in the propensity score matched cohort for PORT vs no PORT in: (A) entire matched
cohort; (B) matched pathologic T4 (pT4) disease; (C) matched node positive disease; (D) matched positive margins; (E) matched both pT4 disease
and positive surgical margins. PORT, postoperative radiotherapy. Green line = PORT, Blue line = No PORT

further support to the change in the National Comprehensive
Cancer Network (NCCN) guidelines that added PORT as
a treatment option to consider for patients with LABC. It

should be noted, however, that the patients included in this
analysis were treated prior to the NCCN guidelines incorporating PORT and it may be that patients referred for PORT in
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benefit for PORT appears to be particularly pronounced for
pT4 disease, positive nodes, and/or positive margins. Phase 3
trials of PORT for patients with LABC are warranted.
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FIGURE 3

Forest plot of patient disease and treatment
characteristics and association with overall survival

this cohort had very poor prognostic factors, which would not
be well‐captured in the NCDB (ie, grossly positive margins).
Although the strengths of our study include the large
number of patients treated in the modern RT era, there are
notable limitations. As an observational study, we were unable to control for all potential confounding factors that may
influence the apparent survival benefit of PORT, though PS
matching helps control for a large number of measured confounders. Key variables are not included in the NCDB, including information on cause of death and recurrence as well
as radiation treatment volumes (ie, pelvis vs cystectomy bed
alone). Detailed information on chemotherapeutic agents (ie,
cisplatin vs noncisplatin based) used and their dosing are also
not available in the NCDB. There is also a possible selection
bias with respect to treatment assignment that cannot be fully
adjusted for on a multivariable analysis and with matching.
Patients receiving PORT may be representative of healthier
patients who can tolerate additional therapy, or conversely,
may be representative of patients with particularly advanced
disease who were referred for a nonstandard adjuvant therapy. We conducted a sensitivity analysis to assess the robustness of our findings to unmeasured confounding to try
to address these limitations. Lastly, in our study, the OS for
patients may be worse than OS reported in clinical trials such
as SWOG 8710 and other institutional retrospective series.1,14
This difference may be related to inclusion of patients with
comorbidities who would have been excluded from a clinical
trial as well as heterogeneity in the radiation dose, treatment
volumes, and chemotherapy administration.28,29 Importantly,
the lack of details on chemotherapeutic regimens used in this
study (eg, chemotherapy agent(s), number of cycles administered, and doses) is a major limitation of the database.
To our knowledge, this is the largest study investigating
the impact of PORT on OS in patients with LABC. Based
on this retrospective analysis, PORT appears to be associated with improved OS and these findings lend support to
the use of PORT. While not definitive, these results suggest
that patients with LABC should be considered for PORT. The

ORCID
Benjamin W. Fischer‐Valuck
org/0000-0003-2348-9710
Ronac Mamtani

https://orcid.

https://orcid.org/0000-0002-8267-5356

Brian C. Baumann
https://orcid.
org/0000-0002-7482-1413
R E F E R E NC E S
1. Christodouleas JP, Baumann BC, He J, et al. Optimizing bladder
cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer. 2014;120(8):1272‐1280.
2. Baumann BC, Sargos P, Eapen LJ, et al. The rationale for post‐
operative radiation in localized bladder cancer. Bladder Cancer.
2017;3(1):19‐30.
3. Herr HW, Faulkner JR, Grossman HB, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin
Oncol. 2004;22(14):2781‐2789.
4. International Collaboration of T, Medical Research Council
Advanced Bladder Cancer Working P, European Organisation for
R, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle‐invasive bladder cancer: long‐term results of the BA06 30894 trial. J
Clin Oncol. 2011;29(16):2171‐2177.
5. Visser O, Nieuwenhuijzen JA, Horenblas S; Members of the
Urological Oncology Working Group of the Comprehensive
Cancer Centre A. Local recurrence after cystectomy and survival
of patients with bladder cancer: a population based study in greater
Amsterdam. J Urol. 2005;174(1):97‐102.
6. Volkmer BG, Kuefer R, Bartsch GC Jr, Gust K, Hautmann RE.
Oncological followup after radical cystectomy for bladder cancer‐is
there any benefit?. J Urol. 2009;181(4):1587‐1593; discussion 1593.
7. Zaghloul MS, Awwad HK, Akoush HH, Omar S, Soliman O, el
Attar I. Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control. Int J Radiat Oncol Biol Phys. 1992;23(3):511‐517.
8. Zaghloul MS, Christodouleas JP, Smith A, et al. Adjuvant sandwich chemotherapy plus radiotherapy vs adjuvant chemotherapy
alone for locally advanced bladder cancer after radical cystectomy:
a randomized phase 2 trial. JAMA Surg. 2018;153(1):e174591.
9. Baumann BC, Guzzo TJ, He J, et al. Bladder cancer patterns of pelvic failure: implications for adjuvant radiation therapy. Int J Radiat
Oncol Biol Phys. 2013;85(2):363‐369.
10. Baumann BC, He J, Hwang W‐T, et al. Validating a local failure risk stratification for use in prospective studies of adjuvant

  

FISCHER‐VALUCK et al.

11.

12.

13.

14.

15.

16.

17.

18.

19.
20.

21.

22.

23.

radiation therapy for bladder cancer. Int J Radiat Oncol Biol Phys.
2016;95(2):703‐706.
Reddy AV, Pariser JJ, Pearce SM, et al. Patterns of failure after
radical cystectomy for pT3‐4 bladder cancer: implications
for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys.
2016;94(5):1031‐1039.
Christodouleas JP, Hwang WT, Baumann BC. Adjuvant radiation
for locally advanced bladder cancer? a question worth asking. Int J
Radiat Oncol Biol Phys. 2016;94(5):1040‐1042.
Baumann BC, Noa K, Wileyto EP, et al. Adjuvant radiation therapy
for bladder cancer: a dosimetric comparison of techniques. Med
Dosim. 2015;40(4):372‐377.
Sargos P, Baumann BC, Eapen LJ, et al. Adjuvant radiotherapy
for pathological high‐risk muscle invasive bladder cancer: time to
reconsider? Transl Androl Urol. 2016;5(5):702‐710.
Maldonado G, Greenland S. A comparison of the performance of model‐
based confidence intervals when the correct model form is unknown:
coverage of asymptotic means. Epidemiology. 1994;5(2):171‐182.
Mitra N, Heitjan DF. Sensitivity of the hazard ratio to nonignorable treatment assignment in an observational study. Stat Med.
2007;26(6):1398‐1414.
Austin PC. Propensity‐score matching in the cardiovascular surgery
literature from 2004 to 2006: a systematic review and suggestions for
improvement. J Thorac Cardiovasc Surg. 2007;134(5):1128‐1135.
Austin PC. The use of propensity score methods with survival or
time‐to‐event outcomes: reporting measures of effect similar to those
used in randomized experiments. Stat Med. 2014;33(7):1242‐1258.
Skinner EC, Stein JP, Skinner DG. Surgical benchmarks for the
treatment of invasive bladder cancer. Urol Oncol. 2007;25(1):66‐71.
Pollack A, Zagars GK, Cole CJ, Dinney CP, Swanson DA, Grossman
HB. The relationship of local control to distant metastasis in muscle invasive bladder cancer. J Urol. 1995;154(6):2059‐2063.
Baumann BC, He J, Hwang W, et al. Robust risk stratification
model predicts local‐regional recurrence after radical cystectomy
in different patient cohorts. [abstract]. Int J Radiat Oncol Biol
Phys. 2013;87(2):S82.
Baumann BC, Guzzo TJ, He J, et al. A novel risk stratification
to predict local‐regional failures in urothelial carcinoma of the
bladder after radical cystectomy. Int J Radiat Oncol Biol Phys.
2013;85(1):81‐88.
Ballas L, Sargos P, Orre M, Bian SX, Daneshmand S, Eapen
LJ. Tolerance of orthotopic ileal neobladders to radiotherapy: a

24.

25.

26.

27.

28.

29.

|

3709

multi‐institutional retrospective study. Clin Genitourin Cancer.
2017.
Baumann BC, Bosch WR, Bahl A, et al. Development and validation of consensus contouring guidelines for adjuvant radiation
therapy for bladder cancer after radical cystectomy. Int J Radiat
Oncol Biol Phys. 2016;96(1):78‐86.
Froehner M, Novotny V, Wirth MP, Brookman‐May S, Aziz A,
May M. External validation of a model to predict locoregional failure after radical cystectomy. Cancer. 2014;120(22):3584.
Ku JH, Kim M, Jeong CW, Kwak C, Kim HH. Risk prediction
models of locoregional failure after radical cystectomy for urothelial carcinoma: external validation in a cohort of korean patients.
Int J Radiat Oncol Biol Phys. 2014;89(5):1032‐1037.
Sargos P, Baumann BC, Eapen L, et al. Risk factors for loco‐regional recurrence after radical cystectomy of muscle‐invasive
bladder cancer: a systematic‐review and framework for adjuvant
radiotherapy. Cancer Treat Rev. 2018;70:88‐97.
Fischer‐Valuck BW, Michalski JM, Contreras JA, et al. A propensity analysis comparing definitive chemo‐radiotherapy for muscle‐invasive squamous cell carcinoma of the bladder vs. urothelial
carcinoma of the bladder using the National Cancer Database. Clin
Transl Radiat Oncol. 2019;15:38‐41.
Fischer‐Valuck BW, Rao YJ, Rudra S, et al. Treatment patterns and
overall survival outcomes of octogenarians with muscle invasive
cancer of the bladder: an analysis of the national cancer database. J
Urol. 2018;199(2):416‐423.

SUPPORTING INFORMATION
Additional supporting information may be found online in
the Supporting Information section at the end of the article.    
How to cite this article: Fischer‐Valuck BW,
Michalski JM, Mitra N, et al. Effectiveness of
postoperative radiotherapy after radical cystectomy
for locally advanced bladder cancer. Cancer Med.
2019;8:3698–3709. https://doi.org/10.1002/cam4.2102

